Navigation Links
A potential new class of fast-acting antidepressant
Date:10/29/2013

More than 1 in 10 Americans take antidepressants, but these medications can take weeksand for some patients, monthsbefore they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.

"One of the biggest problems in the treatment of depression today is a delay in onset of therapeutic effects. There has been a great need to discover faster-acting drugs," said Stephanie Dulawa, PhD, associate professor of psychiatry and behavioral neuroscience at the University of Chicago and senior author of the study.

Delayed onset of antidepressant therapeutics can significantly impact patients, especially those with major depressive disorder, who often spend months switching between ineffective medications. Currently, only two drugsketamine and scopolamineexhibit rapid onset. Due to severe side effects, however, neither is suitable for human use.

In seeking a new class of fast-acting therapeutics, Dulawa and her team tested biological pathways that had previously been shown to generate antidepressant effects but had never been studied for rate of onset. They looked at different subtypes of serotonin receptors, proteins that are binding partners for serotonin, a neurotransmitter that has been shown to regulate mood, memory and appetite.

Of these subtypes, serotonin 2C receptors stood out. Selectively blocking these receptors in mice significantly reduced depression-like behaviors in only five days, compared to a minimum of two weeks for a control antidepressant medication.

"We observed fast-acting therapeutic effects in multiple behavioral tasks after we administered compounds that selectively block serotonin 2C receptors," said Mark Opal, a graduate student at the University of Chicago and lead author of the paper. "We began our measurements at five days, but we think there's a possibility it could be effective even sooner than that."

Serotonin 2C receptors normally inhibit the release of dopamine, another neurotransmitter commonly associated with mood, from certain neurons. When 2C is blocked, the researchers believe, more dopamine is released into regions of the brain such as the prefrontal cortex. The team also observed the induction of biomarkers that indicate antidepressant action.

This is the first new biological mechanism that has shown the ability to rapidly alleviate symptoms of depression since ketamine and scopolamine, and it potentially represents a much safer alternative. Some current antidepressants on the market already affect serotonin 2C receptors, although not selectively, and Dulawa believes the safety profile is favorable for human use. The team is now investigating compounds suitable for clinical trials.

"One of the primary advantages to our discovery is that this is much more of an innocuous target than others that have been identified," Dulawa said.


'/>"/>

Contact: Kevin Jiang
kevin.jiang@uchospitals.edu
773-795-5227
University of Chicago Medical Center
Source:Eurekalert

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports stars, and Hollywood ... failed. Many of these people had lost all hope. Their stories are ... Download (pdf) , “Neil takes readers on a riveting journey through the ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... building management solutions, announced today the opening of an office in Taipei, Taiwan. ... the Greater China region, while developing new relationships in the region. Located in ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... hood and a high-performance fume hood. Along with the advantages and disadvantages of ... ductless vs. ducted hoods in the laboratory. , Attendees will learn from an ...
(Date:9/19/2017)... ... ... CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview with Dr. ... Dr. Harman and Dr. Riordan met in 2003 and have remained in contact over ... cell therapy and a fast friendship was formed. , Dr. Harman has been a leader ...
Breaking Biology Technology: